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Abstract
Purpose We selected and evaluated a comprehensive set of themes that encompass health-related quality of life (HRQOL) 
among HIV patients, which enables clinicians to tailor care to individual needs, follow changes over time and quantify returns 
on health care investments and interventions.
Methods HIV patients (N = 250) of two Dutch HIV clinics were invited to complete an online survey comprised of a set of 
(adaptations of) validated questionnaires measuring eight themes, including general health (SF-12), stigma (short stigma 
scale), social support (SSL12-I), self-esteem (SISE), sexuality problems, anxiety and depression (HADS), sleeping difficul-
ties (SCL90-Sleep) and perceived side-effects.
Results Findings from 170 (response rate 68%) patients (Male = 159, 94.1%) showed that questionnaires had high internal 
consistency, and most themes significantly correlated (r’s .21 to − .69, p < .05) in the expected directions. Exploring cut-off 
scores shows that a significant proportion of patients score outside of the desired range on single themes (between 16.0 and 
73.1%), and many patients on multiple themes simultaneously (8.9% on 5 or more themes). Regression analysis showed that 
social support, self-esteem and sexuality problems were associated with general health (R = .48, R2 = .23, F(4,145) = 10.57, 
p < .001); adding anxiety and depression, sleeping difficulties and perceived side-effects explained 51.2% of the variance in 
total (R = .72, ∆R2 = .29, F(3, 142) = 27.82, p < .001).
Conclusions We succeeded in developing a questionnaire that comprehensively assesses HRQOL. HRQOL of the majority of 
Dutch HIV patients could be improved. The themes strongly influenced each other, therefore insights into any of the themes 
could inform interventions to improve HRQOL, and increase attention to these themes in routine consultations between 
patients and health care professionals.
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Introduction
Hospitals have many sometimes-conflicting goals, such as 
patient-centredness, safety, quality, cost-effectiveness. To 
achieve these goals clear aims have to be set, while the over-
arching goal of health care is to improve patients’ health out-
comes. Value Based Health Care (VBHC) aims to improve 
patient value, by focusing on their health outcomes, instead 
of process factors. These outcomes are divided by the cost 
of care, resulting in highest value for patients [1, 2]. To 
determine value or quality of care, clearly defined measur-
able outcomes are needed. These outcomes can be divided 
in three tiers, outcomes related to survival and mortality, 
outcomes related to recovery and finally outcomes related 
to sustainability [2]. In VBHC, it is further stated that value 
should be measured for defined groups with similar needs. 
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One such group is patients living with human immunodefi-
ciency virus (HIV).
In the Netherlands, HIV care is freely accessible in 26 
designated hospitals. The OLVG hospital has the largest 
HIV clinic in the country, and started to organize its HIV 
care according to the principles of VBHC for quality of 
care monitoring. In close collaboration with patients several 
outcome indicators were defined, varying form measurable 
medical parameters like viral control and cardiovascular 
risk, but also patient related outcomes like health-related 
quality of life (HRQOL), both related to sustainability [2]. 
Assessment of HRQOL can be useful to tailor care, since it 
enables caregivers to focus on individual needs during con-
sultations. Furthermore, systematic assessment of changes in 
HRQOL over time can serve to monitor and evaluate inter-
ventions and quantify returns on health care investments [3].
HRQOL refers to how health impacts people’s ability 
to function in daily life and their perceived well-being in 
physical, mental and social domains of life [4]. Previous 
studies have already shown that being diagnosed with HIV 
or AIDS and experiencing disease-related symptoms is asso-
ciated with lower HRQOL [3, 5–9]. Furthermore, HRQOL 
is directly associated with clinically relevant outcomes in 
HIV positive patients, such as treatment adherence and viral 
suppression [10, 11]. Adherence to HIV treatment and viral 
suppression are important to improve treatment effectiveness 
[12–15], prevent development of drug-resistant HIV-strains, 
and onward transmission of HIV [16–18].
Based on literature, expert opinion and discussions with 
patients eight themes were identified as important determi-
nants for HRQOL. A previous qualitative study interviewing 
patients identified themes that were important to patients 
[19]. These themes were discussed with expert internists, 
HIV nurses and psychiatrists from the OLVG hospital, 
whom also indicated that sleeping problems and experi-
enced side-effects should be assessed. Finally, the literature 
was consulted, and themes that both influenced HRQOL 
and clinically relevant outcomes among HIV patients were 
included (Table 1). The comprehensive set of question-
naires therefore included general health (also often used as 
a HRQOL measure); and several psychological themes, such 
as stigma, social support, self-esteem and sexuality prob-
lems (including both questions on dysfunctions but also 
satisfaction). In addition, we measured the clinical themes 
anxiety and depression, sleeping difficulties and perceived 
side-effects. In previous studies, most of the themes have 
been investigated separately, in combination with only few 
other determinants or using just one or two items to assess 
separate themes. When multiple themes are assessed almost 
all themes are found to be interrelated. In Table 1, we have 
provided an overview of established relations between the 
themes, and effects themes reported to have on clinically 
relevant HIV outcomes.
The objective of our study was to explore the psychomet-
ric qualities of the questionnaires, the associations between 
the themes, and HRQOL among HIV patients receiving care 
in the Netherlands. The comprehensive set of themes that 
encompass HRQOL among HIV positive patients was evalu-
ated, independently of influencing factors such as gender, 
sexual orientation and other social demographic variables.
Methods
Participants and procedure
Patients visiting the HIV out-patient clinics (OLVG Amster-
dam and the Catharina Hospital Eindhoven (CZE)) between 
21 April 2016 and 21 May 2016 were asked to participate by 
the HIV nurse or doctor during their routine consultations. 
Inclusion criteria were age over 18 years, and proficient in 
the written Dutch or English language, as the questionnaire 
was only available in Dutch and English. In total 250 patients 
agreed to receive an email with an invitational link to the 
online survey. In the OLVG, HIV nurse provided informa-
tion and informed consent was signed on side, thereafter the 
link to the questionnaire was sent. In the CZE, practically 
receiving all information and signing the informed consent 
was not possible. Therefore, patients who indicated to be 
willing to participate received more information through 
the link, including contact information for questions, sub-
sequently an online informed consent followed. After the 
informed consent, the questionnaire followed, which took 
approximately 15 min to complete.
The Dutch Medical Research Involving Human Subjects 
Act (Dutch acronym: WMO) does not apply for this study, 
because no particular behaviour is imposed on participants 
and there were no (medical) interventions other than routine 
clinical care. A waiver for full medical ethical review was 
obtained from Medical Research Ethics Committee United 
(MEC-U).
Measures
The measures of the eight chosen themes had to fulfil several 
criteria. The questionnaires had to be (a) shown reliable and 
valid, preferably previously tested on Dutch HIV patients; 
(b) reasonably short; (c) suited for patients with HIV; (d) 
used in previous studies, preferably often and in many con-
texts and (e) preferably provide (clinically) relevant cut-off 
points.
Quality of life was assessed with the Short-Form-12 
Health Survey (SF-12) [20]. Ware et al. [20] argued that 
the abbreviated SF-12 validly covers HRQOL and the two 
subscales: physical and mental health. We used the standard 
recall period of 4 weeks [21]. Scores range from 0 to 100 
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(reflecting worst to best health). As we do not have norm 
scores for our population we analysed scores on the 0-100 
scale, with a cut-off criterion of 50 [20].
Anxiety and depression was measured using the 14 items 
of the Hospital Anxiety and Depression Scale (HADS), with 
two subscales seven items each [22]. Scores on the total 
scale range from 0 to 42; higher scores represent more dis-
tress. A cut-off of 15 on the total scale was used to identify 
people with a potential depressive disorder [23]. The scores 
on both subscales range from 0 to 21. As suggested by Bjel-
land and colleagues we employed a cut-off of nine to identify 
potential clinical cases of anxiety and depression [24].
Stigma was assessed with a ten-item scale, which is an 
abbreviated version of the often used Berger Stigma scale 
[25, 26]. It contains the following subscales: “Personalized 
Stigma”, “Disclosure Concerns”, “Negative Self-Image” and 
“Public Attitudes”. Average scores were reported, higher 
average scores indicated greater stigma on the total scale 
and subscales (range 1–5).
Social support was investigated with the 12-item short 
version of the Social Support List—Interaction with good 
psychometric properties (SSL-12-I) [27–29]. The scores 
range from 12 to 48, with higher scores indicating more 
social support. This scale has three subscales, namely 
“Everyday support”, “Support in problem situations” and 
“Esteem support”.
The Sexuality Problems questions were adapted from the 
model of Incentive Motivation [30] and the Natsal-SF [31]. 
Table 1  Themes that encompass health-related quality of life among HIV positive patients, and the associations with clinical and psychological 
outcomes, and medical HIV-related health outcomes, including the expected directions of the associations (positive or negative)
The plus (+) and minus (−) signs reflect the directions of the associations (positive or negative). For example, Stigma (−) in the first column and 
row means a negative association between quality of life and stigma, as quality of life increases stigma decreases
HIV human immunodeficiency virus
Themes Clinical and psychological outcomes HIV-related health outcomes
Quality of life (physical and 
mental health)
Stigma (−) [54, 62]
Social support (+) [51, 62, 63]
 Physical health [64]
Self-esteem (+) [65]
Sexuality problems (−) [66]
Anxiety and depression (−) [51]
Sleeping difficulties (−) [67]





Stigma Quality of life (−) [44, 54, 55]
Social support (−) [25, 43, 44, 54, 62, 70]
Self-esteem (−) [25, 43, 44, 54]
Sexuality problems (+) [66]
Anxiety and depression (+) [25, 54, 62, 70, 71]
Sleeping difficulties (no association found)
Perceived side-effects (+) [54]
Engagement in care (−) [72]
Treatment adherence (−) [43, 72]
HIV symptoms (+) [70]
Social support Quality of life (+) [73]
Self-esteem (+) [43, 44]
Sexuality problems (no association)
Anxiety and depression (−) [43, 62, 71]
Sleeping difficulties (∓) [74]
Perceived side-effects (−) [63]
Indirect effect, offer coping mechanism for other themes 
that do affect medical HIV outcomes directly [43, 44, 
65, 73]
Self-esteem Quality of life (+) [44]
Sexuality problems (−) [75]
Anxiety and depression (−) [44]
Sleeping difficulties (−) [76]
Perceived side-effects (no association)
Sexuality problems Quality of life (−) [66, 77]
Anxiety and depression (+) [66]
Sleeping difficulties (+) [78]
Perceived side-effects (+) [66]
Treatment adherence (−) [66, 79]
Anxiety and depression Quality of life (−) [71, 80, 81]
Sleeping difficulties (+) [82]
Perceived side-effects (+) [83]
Treatment adherence (−) [84]
Treatment outcomes (−), functionality (−), and mortality 
(+) [71]
Sleeping difficulties Quality of life (−) [5, 77]
Perceived side-effects (+) [79]
Disease severity (+) [77, 79]
Perceived side-effects Quality of life (−) [79] Treatment adherence (−) [79, 85]
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Our scale consists of two subscales with five-point answer 
scales, namely “Sexual functioning and experience” (five 
items; “Do you have trouble with getting or keeping an erec-
tion”). The second subscale was “Sexual feelings” (three 
items; “Do you feel anxious about having sex, because you 
are afraid of passing HIV to others”). Average scores were 
reported, higher average scores indicated greater stigma on 
the total scale and subscales (range 1–5).
Self-esteem was measured using the Single-Item Self-
Esteem scale (SISE), on a scale from 1 (not very true of 
me) to 7 (very true of me) [32]. Robins et al. [32] provided 
support for the construct validity of this measure; the SISE 
was highly convergent with the Rosenberg Self-esteem Scale 
[33].
Sleeping difficulties were surveyed with the Sleep Diffi-
culties scale from the Dutch version of the Symptom Check-
list-90- Revised (SCL-90-R) [34, 35], following the method 
of Boelen and Lancee [36]. This scale instructs respond-
ents to rate the presence of three symptoms during the pre-
ceding week answered on a five-point scale (1 = not at all, 
5 = extremely). We assessed the sum score (range 3–15), 
higher scores reflecting more sleep difficulties. The cut-off 
we use was 4.5, which is the score of the average Dutch 
population [34].
Side-effects were measured using a single item: “To what 
extend do you have the experience that the HIV medica-
tion gives you side-effects?” answered on a ten-point scale 
(1 = not at all, 10 = very much). We do not expect severe 
side-effects, because this would lead to a switch of medi-
cation regiment, therefore validated measures, including 
lengthy lists of symptoms, were not included in our ques-
tionnaire [35, 37].
Data analysis
The questionnaire in the OLVG was programmed in Quest-
manager [38] to be able to use the outcomes during routine 
consultations, which guaranteed safety of the patient data. 
In the CZE the questionnaire was programmed in EasyRe-
search [39], and data collected anonymously only for the 
purpose of this study. To examine the psychometric prop-
erties of our scales, we calculated the internal consistency 
of all total scales (Cronbach’s alpha). Subsequently, we 
performed principal-components analysis with orthogonal 
Varimax rotation, extracting factors with Eigenvalues of one 
or higher [40, 41].
We calculated the total score and subscales scores for 
our patients on each of the themes, investigated correla-
tions. In addition, we assessed scores related to clinical 
cut-off scores if available. When a clinical cut-off score 
was lacking, we used quartiles to divide the participants 
in four groups to determine upper and lower limits to get 
some insight into the distribution of patients. We explored 
how many participants score outside of the desired range 
on the questionnaires (i.e. upper or lower quartile depend-
ing on the scale).
To explore relevance of the chosen set of questionnaires, 
we performed a hierarchical linear regression analysis on the 
SF-12 scores and the HADS scores, first adding psychologi-
cal themes; stigma, social support, self-esteem and sexuality 
problems. Then we added clinical measures (anxiety and 
depression, sleeping difficulties and side-effects). Finally, in 
a third step we added gender and location of the HIV clinic 
where the participants were treated.
Results
Participants
In total 170 HIV positive out-patients participated (response 
rate 68%). Participants were patients of the CZE or OLVG 
(43 patients, 24.9% and 127 patients, 75.1% respectively), 
159 (94.1%) of the participants were men. One person was 
an HIV negative partner of one of the patients and was 
excluded from the analysis.
Psychometric properties of the questionnaires
All questionnaires and subscales had high internal consist-
ency (Table 2), Cronbach’s alpha between .69 (acceptable) 
and .90 (excellent). Factor analysis extracted the number 
of subscales that were expected based on the subscales 
in reported in the literature, and questions loaded on the 
factors belonging to the expected subscale. In the HADS, 
we unexpectedly found a third factor, only one item loads 
strongest on this factor (“I can enjoy a good book or radio 
or TV programme”). In the stigma questionnaire, the two 
items of the “Public Attitudes” subscale, loaded on “Person-
alized stigma” and “Negative self-image”. Consistent with 
the original HADS and Stigma scale repeating the analysis 
with forced factor outcomes confirmed the expected HADS 
and Stigma subscales. The internal consistency and found 
structures of the questionnaires warrant continuing with 
assessing the bidirectional association between the scales.
Almost all scales were correlated, and correlated in 
the expected directions (Table 3), based on the literature 
(Table 1). Additionally, the subscales of all questionnaires 
showed the same pattern of associations as the total scales 
(data not shown). Only the stigma scale did not correlate 
significantly with many of the themes, except for the HADS 
depression subscale (r = .16, p < .001), and on the sexual-
ity problems questionnaire, the subscale for sexual feelings 
(r = .33, p < .001).
2689Quality of Life Research (2019) 28:2685–2694 
1 3
Health‑related quality of life among HIV positive 
people
Using the cut-off scores (Table 2), four (2.4%) patients 
scored within the desired range on all of the questionnaires; 
whereas 45 (26.6%) patients scored outside of the desired 
range on just one of the questionnaires, 56 (33.1%) on two 
of the questionnaires, 33 (19.5%) on three of the question-
naires, 16 (9.5%) on four of the questionnaires, 10 (5.9%) 
on five of the questionnaires, 3 (1.8%) on six of the ques-
tionnaires, 2 (1.2%) on seven of the questionnaires. None of 
the patients scored outside of the desired range on all of the 
questionnaires.
SF-12 scores were significantly predicted through 
a hierarchical linear regression with the psychological 
themes: Social Support, Self-esteem and Sexuality prob-
lems (see Table 4). Sexuality problems and Self-esteem 
were the strongest predictors (both p’s < .01), followed 
by Social Support (p < .03). Notably, Stigma did not pre-
dict SF-12 Health scores. The percentage of explained 
variance was 22.6% (R = .48). Adding HADS scores, 
Sleeping Difficulties and Experienced Side-effects to the 
regression, with HADS scores (p < .001) as strongest pre-
dictor followed by Experienced Side-effects (p < .05). The 
percentage of explained variance significantly increased 
to 51.2% (R = .72, ∆R2 = .29). The ANOVA from the 
overall regression equation revealed a statistically sig-
nificant result for both Step 1, F(4,145) = 10.57, p < .001, 
and Step 2, F(3, 142) = 27.82, p < .001. Finally, adding 
gender and out-patient clinic (CZE or OLVG, p’s > .90) 
to the regression did not increase the explained variance, 
F(2,140) = 0.01, p = .992.
As the HADS scores were predictive in the predication of 
the SF12 scores, we performed a similar hierarchical linear 
regression with HADS scores as outcome. Social Support, 
Self-esteem and Sexuality problems were also significantly 
associated with HADS scores (p’s < .04), with Self-esteem 
as most salient variable. These variables explained 39.6% 
(R = .63) of the total variance, F(4,145) = 23.81, p < .001. 
Adding Sleeping Difficulties (p = .003) and Experienced 
Side-effects (p = .260) to the regression, with Self-esteem, 
Sleeping difficulties and Social Support scores as most sali-
ent variable (p’s < .009). The percentage of explained vari-
ance significantly increased 44.3% (R = .67, ∆R2 = .05). The 
ANOVA from the overall regression equation also revealed 
a statistically significant result for Step 2, F(2,143) = 5.95, 
p = .003. Finally, adding gender and out-patient clinic to 
the regression did not significantly increase the percentage 
Table 2  Mean scores, standard 
deviations (SDs), Cronbach’s 
alphas (α), cut-off scores (C), 
and number (#) and percentage 
(%) of people scoring 
suboptimal on all quality of life 
questionnaires of HIV positive 
patients (N = 170) of the 
Catharina Hospital Eindhoven 
and OLVG Amsterdam
HIV human immunodeficiency virus, SD standard deviation
*Based on literature, if not available based on lower (Q1) or upper (Q4) quartile
Mean SD Cronbach’s α Cut-off* Number 
suboptimal
%
Quality of life 69.08 17.46 .80 50 26 16.0
Anxiety and depression 9.62 6.99 .90 15 44 26.0
Stigma 2.03 0.53 .83 Q4: 2.4 37 23.7
Social support 30.99 7.55 .93 Q1: 26 51 31.1
Self-esteem 5.00 1.63 – Q1: 4.2 38 24.5
Sexuality problems 2.40 0.79 .80 Q4: 2.9 38 24.4
Sleeping difficulties 6.66 2.80 .69 4.5 115 73.1
Perceived side-effects 3.54 2.51 – Q4: 4.0 35 22.7
Table 3  Significant 
correlations of all quality of life 
questionnaires of HIV positive 
patients (N = 170) of the 
Catharina Hospital Eindhoven 
and OLVG Amsterdam
The minus sign (−) reflects that some of the correlations are negative
HIV human immunodeficiency virus, SD standard deviation
1 2 3 4 5 6 7 8
1 Quality of life
2 Anxiety and depression − .69
3 Stigma – –
4 Social Support .35 − .46 − .35
5 Self-esteem .36 − .56 – .42
6 Sexuality Problems − .35 .34 .33 − .34 –.28
7 Sleeping difficulties − .37 .44 – − .28 .33 − .30
8 Perceived side-effects − .33 .25 .21 − .25 – .37 .24
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of explained variance (R2 = .462, R = .68, ∆R2 = .02, 
F(2,141) = 2.54, p = .083).
General discussion
In this study, we introduce a set of questionnaires for the 
assessment of the HRQOL among HIV patients during rou-
tine clinical practice, but that can also be used to evaluate 
the separate themes that encompass HRQOL. Our findings 
showed that the majority of our patients did score outside 
of the desired range on one or more of our themes. These 
findings are in line with previous studies that already showed 
that being diagnosed with HIV is associated with lower 
HRQOL [3, 5–9]. Notably, in the scales with quartiles as 
cut-off approximately 25% of the participants scored outside 
of the desired range, therefore this might exclude people 
who are experience mild but still clinically relevant issues.
Our questionnaires showed excellent psychometric prop-
erties; including the measure we adapted ourselves for sexu-
ality problems. We also found that practically all themes 
were associated with each other in the directions expected by 
the literature (Table 1). Furthermore, stigma, social support, 
self-esteem as well as sexuality problems were associated 
with HRQOL in a regression analysis. This is important, 
even though both social support and self-esteem are not 
directly linked to clinically relevant HIV health outcomes. 
Social support has been shown to reduce stress experienced 
because of suffering from long-term illness in general [42], 
and living with HIV in particular [43]. When people experi-
ence some stress, simply being involved in a network, having 
people around, and feeling part of a group can serve as a 
buffer against stress and positively affect HRQOL. Similarly, 
self-esteem, which does influence some of the other themes, 
could also function as a coping mechanism and positively 
affect HRQOL in HIV patients [44]. Through these direct 
and indirect routes, social support and self-esteem could 
influence clinically relevant outcomes.
Adding anxiety and depression, sleeping difficulties and 
perceived side-effects in the regression obscured the associa-
tions between the psychological themes and HRQOL. Social 
support and self-esteem were also related to anxiety and 
depression scores, even after adding sleeping difficulties and 
perceived side-effects. These findings underscore the impor-
tance of systematically measuring themes, in order not to 
miss the potentially important role of stigma, social support 
and self-esteem at the expense of the strong association of 
anxiety and depression with HRQOL scores.
The separate questionnaires in our survey have been used 
in other populations, making some comparisons possible 
qualifying the condition of Dutch HIV patients compared 
to HIV patient in other countries or other subpopulations. 
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less anxiety and depression compared to HIV positive 
patients from Canada [45]. A study showed that the gen-
eral Dutch population (18–65 years) scored lower on anxi-
ety and depression, but Dutch general medical patients and 
psychiatric out-patients scored higher than our HIV positive 
patients [46]. Furthermore, these patients experienced less 
stigma compared to 212 young (16–29 years) people liv-
ing with HIV in the United States [47]. These patients also 
experienced more social support compared to Dutch elderly 
[29] or Dutch people, who had a stroke 3 years ago [48]. In 
contrast, our HIV patients experienced less social support 
than Dutch patients with spinal cord injury [49]. In addi-
tion, these patients were higher in self-esteem than under-
graduate students of an American University [32]. In a study 
that looked at self-esteem across different ages, our HIV 
patients also scored higher than the highest score age group 
(60–69 years) [50]. Finally, these participants had more 
sleeping difficulties compared to the Dutch general popu-
lation, but less than people, who suffered from prolonged 
grieving disorder before treatment [34, 36]. A review has 
shown that HRQOL is influenced by several determinants, 
and studies measuring HRQOL usually do not include all 
and the same determinants [51]. Therefore, it is important 
to assess multiple themes together when evaluating HRQOL 
in routine clinical care.
Currently, even though the regressions and correlations 
indicate the relevance of the themes for our HIV patients, we 
have not yet linked the scores on the questionnaires to other 
outcome parameters, such as therapy effectiveness, cardio-
vascular risk and therapy toxicity, nor did we correlate it 
with patient characteristics. An important next step will be 
to monitor the themes, their trends over time, and to predict 
or even influence medical outcomes by offering successful 
interventions to improve HRQOL.
Strengths and limitations
A strength of this study is that it is a first step to comprehen-
sively measure HRQOL among HIV patients in the Nether-
lands. Currently, possible undiagnosed cases of depression 
are already identified and referred for further psychiatric 
treatment. However, for several questionnaires clinically rel-
evant cut-off values need to be determined to guide potential 
interventions. Moreover, for many themes proven effective 
interventions are not yet available and need to be developed.
A second strength is that the response rate in our study 
[52, 53] compared to other studies with online survey our 
response rate is high, even though some of the topics could 
be perceived as sensitive. This illustrates that participants 
probably view HRQOL as important, and therefore had a 
high willingness to participate.
In this first examination, a relatively small number of 
people participated, and we wanted to keep the request to 
patients minimal, therefore we have not assessed extensive 
demographical characteristic and have not requested consent 
to link this data to the electronic patient files. Consequently, 
we have not stratified for baseline characteristics, such as 
gender, age, migration background, HIV history and concur-
rent co-morbidities. In the near future, we will evaluate the 
value of these questionnaires in a larger population, where 
we can analyse the influence of these factors.
Literature shows that stigma is strongly associated with 
HRQOL in people living with HIV [54–56]. Studies have 
also shown that stigma is related to depression in India 
[57], South-Africa [58] and the United States [59]. Some 
of these studies are focusing on severe stigma, including 
denial of HIV care, evictions from homes and termination 
of employment [57, 58]. In our study we could not demon-
strate an association between stigma and either HRQOL or 
anxiety and depression scores. Although, people living with 
HIV in Netherlands do experience stigma, it appears less 
severe what might explain the reduced impact on anxiety 
and depression. It is suggested that the association between 
stigma and depression might be driven through disclosure 
avoidance (and resulting lack of social support) [60]. Indeed, 
we found that social support was associated with HRQOL 
and anxiety and depression. Nevertheless, other factors we 
have not assessed might also play a role, such as the amount 
of time people have been living with HIV (time reduced 
both stigma and depression) [61]. Finally, we might have 
to focus on the subscales of stigma to get a clearer view of 
the association between stigma, HRQOL and anxiety and 
depression. Negative self-image and public attitudes might 
influence HRQOL directly, whereas personalized stigma and 
disclosure concerns might indirectly affect HRQOL through 
for instance social support [43, 62]. HIV stigma is a multidi-
mensional complex theme, therefore, future research should 
determine if using this abbreviated scale [26] among Dutch 
people living with HIV is warranted.
Conclusion
We succeeded in developing a questionnaire that compre-
hensively assesses HRQOL among HIV positive patients 
during routine clinical practice. Using this questionnaire 
showed that the HRQOL among Dutch HIV patients could 
be improved. Insights into these themes could inform inter-
ventions to improve HRQOL, and at least increase attention 
to these themes in routine consultations between patients 
and health care professionals. Measuring HRQOL could 
thus serve as an intervention in itself, which is in the tradi-
tion of VBHC [2]. Currently, this survey is administered 
yearly among all HIV out-patients in care at the OLVG, to 
2692 Quality of Life Research (2019) 28:2685–2694
1 3
be able to discuss relevant outcomes with patients in their 
routine consultations; other hospitals are also starting to 
measure HRQOL using the same themes and questionnaires. 
In time, we aim to include all hospitals in the Netherlands 
(and maybe beyond) to provide high quality, identical, but 
patient-centred HIV care, to all people living with HIV.
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